Shares of Cronos Group Inc. (TSE:CRON – Get Free Report) fell 0.6% during trading on Monday. The stock traded as low as C$4.62 and last traded at C$4.66. 106,484 shares were traded during mid-day trading, a decline of 33% from the average session volume of 159,142 shares. The stock had previously closed at C$4.69.
Analysts Set New Price Targets
Separately, TD raised their target price on shares of Cronos Group from C$5.50 to C$6.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of C$4.92.
View Our Latest Report on CRON
Cronos Group Price Performance
The company has a debt-to-equity ratio of 0.12, a current ratio of 16.18 and a quick ratio of 24.01. The company has a 50-day moving average price of C$4.62 and a two-hundred day moving average price of C$3.95. The company has a market cap of C$1.72 billion, a PE ratio of 24.53, a P/E/G ratio of 0.12 and a beta of 1.29.
Cronos Group (TSE:CRON – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported C$0.13 earnings per share for the quarter. The business had revenue of C$75.31 million during the quarter. Cronos Group had a net margin of 38.95% and a return on equity of 6.46%. Sell-side analysts expect that Cronos Group Inc. will post -0.26 earnings per share for the current fiscal year.
About Cronos Group
Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT and Lord Jones. For more information about Cronos and its brands, please visit: thecronosgroup.com.
Featured Articles
- Five stocks we like better than Cronos Group
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.
